, Volume 24, Issue 3, pp 183–194

Current Status of Vascular Endothelial Growth Factor Inhibition in Age-Related Macular Degeneration

Review Article


Angiogenesis, the process by which new vessels are created from pre-existing vasculature, has become the subject of intense research in recent years. Increased rates of angiogenesis are associated with several disease states, including cancer, age-related macular degeneration (AMD), psoriasis, rheumatoid arthritis, and diabetic retinopathy. Vascular endothelial growth factor (VEGF) is an important modulator of angiogenesis, and has been implicated in the pathology of a number of conditions, including AMD, diabetic retinopathy, and cancer. AMD is a progressive disease of the macula and the third major cause of blindness worldwide. If not treated appropriately, AMD can progress to involve both eyes. Until recently, the treatment options for AMD have been limited, with photodynamic therapy (PDT) the mainstay of treatment. Although PDT is effective at slowing disease progression, it rarely results in improved vision. Several therapies have been or are now being developed for neovascular AMD, with the goal of inhibiting VEGF. These VEGF inhibitors include the RNA aptamer pegaptanib, partial and full-length antibodies ranibizumab and bevacizumab, the VEGF receptor decoy aflibercept, small interfering RNA-based therapies bevasiranib and AGN 211745, sirolimus, and tyrosine kinase inhibitors, including vatalanib, pazopanib, TG 100801, TG 101095, AG 013958, and AL 39324. At present, established therapies have met with great success in reducing the vision loss associated with neovascular AMD, whereas those still under investigation offer the potential for further advances. In AMD patients, these therapies slow the rate of vision loss and in some cases increase visual acuity. Although VEGF-inhibitor therapies are a milestone in the treatment of these disease states, several concerns need to be addressed before their impact can be fully realized.


  1. 1.
    Mousa S. Mechanisms of angiogenesis in vascular disorders: potential therapeutic targets. In: Mousa S, Landes R, editors. Angiogenesis inhibitors and stimulators: potential therapeutic implications. Georgetown (TX): Eurekah. com/Landes Bioscience, 2000: 1–12Google Scholar
  2. 2.
    Relf M, LeJeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57(5): 963–9PubMedGoogle Scholar
  3. 3.
    Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999; 5(12): 1359–64PubMedCrossRefGoogle Scholar
  4. 4.
    Fink AM, Cauza E, Hassfeld W, et al. Vascular endothelial growth factor in patients with psoriatic arthritis. Clin Exp Rheumatol 2007; 25(2): 305–8PubMedGoogle Scholar
  5. 5.
    Murakami M, Iwai S, Hiratsuka S, et al. Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages. Blood 2006; 108(6): 1849–56PubMedCrossRefGoogle Scholar
  6. 6.
    Mousa SA, Mousa AS. Angiogenesis inhibitors: current and future directions. Curr Pharm Des 2004; 10(1): 1–9PubMedCrossRefGoogle Scholar
  7. 7.
    Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2(10): 727–39PubMedCrossRefGoogle Scholar
  8. 8.
    Casanovas O, Hicklin DJ, Bergers G, et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8(4): 299–309PubMedCrossRefGoogle Scholar
  9. 9.
    Marx J. Cancer research: obstacle for promising cancer therapy. Science 2002; 295(5559): 1444PubMedCrossRefGoogle Scholar
  10. 10.
    Raez LE, Cassileth PA, Schlesselman JJ, et al. Allogeneic vaccination with a B7.1 HLA-HLA gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004; 22(14): 2800–7PubMedCrossRefGoogle Scholar
  11. 11.
    Nemunaitis J, Dillman RO, Schwarzenberger PO, et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 2006; 24(29): 4721–30PubMedCrossRefGoogle Scholar
  12. 12.
    Suzuki E, Kapoor V, Cheung HK, et al. Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity. Clin Cancer Res 2004; 10(17): 5907–18PubMedCrossRefGoogle Scholar
  13. 13.
    de Jong FA, Kehrer DF, Mathijssen RH, et al. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study. Oncologist 2006; 11(8): 944–54PubMedCrossRefGoogle Scholar
  14. 14.
    Spilsbury K, Garrett KL, Shen WY, et al. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol 2000; 157 (1): 135–44Google Scholar
  15. 15.
    Brown LF, Detmar M, Claffey K, et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 1997; 79: 233–69PubMedGoogle Scholar
  16. 16.
    Joukov V, Kaipainen A, Jeltsch M, et al. Vascular endothelial growth factors VEGF-B and VEGF-C. J Cell Physiol 1997; 173(2): 211–5PubMedCrossRefGoogle Scholar
  17. 17.
    Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor: multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991; 266(18): 11947–54PubMedGoogle Scholar
  18. 18.
    Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999; 77(7): 527–43PubMedCrossRefGoogle Scholar
  19. 19.
    Dvorak HF, Nagy JA, Feng D, et al. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyper-permeability in angiogenesis. Curr Top Microbiol Immunol 1999; 237: 97–132PubMedCrossRefGoogle Scholar
  20. 20.
    Senger DR, Van de Water L, Brown LF, et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 1993; 12(3–4): 303–24PubMedCrossRefGoogle Scholar
  21. 21.
    Clauss M, Gerlach M, Gerlach H, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990; 172(6): 1535–45PubMedCrossRefGoogle Scholar
  22. 22.
    Pettersson A, Nagy JA, Brown LF, et al. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest 2000; 80(1): 99–115PubMedCrossRefGoogle Scholar
  23. 23.
    Hirawat S, Elfring G, Northcutt V, et al. Phase 1 studies assessing the safety, PK, and VEGF-modulating effects of PTC299, a novel VEGF expression inhibitor. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part 1; 25(18 Suppl.): 3562Google Scholar
  24. 24.
    Gragoudas ES, Adamis AP, Cunningham Jr ET, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351(27): 2805–16PubMedCrossRefGoogle Scholar
  25. 25.
    Chakravarthy U, Adamis AP, Cunningham Jr ET, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006; 113(9): 1508.31–25Google Scholar
  26. 26.
    Wolowacz SE, Roskell N, Kelly S, et al. Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK. Pharmacoeconomics 2007; 25(10): 863–79PubMedCrossRefGoogle Scholar
  27. 27.
    Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355(14): 1419–31PubMedCrossRefGoogle Scholar
  28. 28.
    Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006; 113(4): 633.e1–4CrossRefGoogle Scholar
  29. 29.
    Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355(14): 1432–44PubMedCrossRefGoogle Scholar
  30. 30.
    Dadgostar H, Ventura AA, Chung JY, et al. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmology 2009; 116(9): 1740–7PubMedCrossRefGoogle Scholar
  31. 31.
    Schouten JS, La Heij EC, Webers CA, et al. A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2009; 247(1): 1–11PubMedCrossRefGoogle Scholar
  32. 32.
    Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Opthalmol 2006; 113(3): 363–72CrossRefGoogle Scholar
  33. 33.
    Bashshur ZF, Schakel A, Hamam RN, et al. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. Arch Ophthalmol 2007; 125: 1357–61PubMedCrossRefGoogle Scholar
  34. 34.
    Hahn R, Sacu S, Michels S, et al. Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age-related macula degeneration. Ophthalmologe 2007; 104(7): 588–93PubMedCrossRefGoogle Scholar
  35. 35.
    Lazic R, Gabric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007; 245: 68–73PubMedCrossRefGoogle Scholar
  36. 36.
    Nguyen QD, Shah SM, Hafiz G, et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006; 113(9): 1522.e1–14CrossRefGoogle Scholar
  37. 37.
    Dixon JA, Oliver SC, Olson JL, et al. VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs 2009; 18(10): 1573–80PubMedCrossRefGoogle Scholar
  38. 38.
    Singerman L. Combination therapy using the small interfering RNA bevasiranib. Retina 2009; 29(6 Suppl.): S49–50PubMedCrossRefGoogle Scholar
  39. 39.
    Xia XB, Xiong SQ, Xu HZ, et al. Suppression of retinal neovascularization by shRNA targeting HIF-1alpha. Curr Eye Res 2008; 33(10): 892–902PubMedCrossRefGoogle Scholar
  40. 40.
    Forooghian F, Das B. Anti-angiogenic effects of ribonucleic acid interference targeting vascular endothelial growth factor and hypoxia-inducible factor-1alpha. Am J Ophthalmol 2007; 144(5): 761–8PubMedCrossRefGoogle Scholar
  41. 41.
    Busch T. Approaches toward combining photodynamic therapy with pharmaceuticals that alter vascular microenvironment. Retina 2009; 29(6 Suppl.): S36–8PubMedCrossRefGoogle Scholar
  42. 42.
    Maier MM, Feucht N, Fiore B, et al. Photodynamic therapy with verteporfin combined with intravitreal injection of ranibizumab for occult and classic CNV in AMD. Klin Monatsbl Augenheilkd 2009; 226(6): 496–502PubMedCrossRefGoogle Scholar
  43. 43.
    Potter MJ, Claudio CC, Szabo SM. A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study. Br J Ophthalmol. Epub 2009 Jun 10Google Scholar
  44. 44.
    Kaiser PK, Boyer DS, Garcia R, et al. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2009; 116(4): 747–55, 755.e1PubMedCrossRefGoogle Scholar
  45. 45.
    Yip PP, Woo CF, Tang HH, et al. Triple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone. Br J Ophthalmol 2009; 93(6): 754–8PubMedCrossRefGoogle Scholar
  46. 46.
    Colquitt JL, Jones J, Tan SC, et al. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess 2008; 12(16): iii–iiv, ix-201PubMedGoogle Scholar
  47. 47.
    Lommatzsch A, Heimes B, Gutfleisch M, et al. Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments. Eye 2009; 23(12): 2163–8PubMedCrossRefGoogle Scholar
  48. 48.
    Landa G, Amde W, Doshi V, et al. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration. Ophthalmologica 2009; 223(6): 370–5PubMedCrossRefGoogle Scholar
  49. 49.
    Takahashi H, Obata R, Tamaki Y. A novel vascular endothelial growth factor receptor 2 inhibitor, SU 11248, suppresses choroidal neovascularization in vivo. J Ocul Pharmacol Ther 2006; 22(4): 213–8PubMedCrossRefGoogle Scholar
  50. 50.
    Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24(1): 25–35PubMedCrossRefGoogle Scholar
  51. 51.
    Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64(19): 7099–109PubMedCrossRefGoogle Scholar
  52. 52.
    Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23(5): 965–72PubMedCrossRefGoogle Scholar
  53. 53.
    Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005; 92(10): 1855–61PubMedCrossRefGoogle Scholar
  54. 54.
    Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356(2): 125–34PubMedCrossRefGoogle Scholar
  55. 55.
    Ratain M, Eisen T, Stadler W, et al. Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2005 ASCO Annual Meeting Proceedings; 23(16 Suppl.): 4544Google Scholar
  56. 56.
    Traxler P, Allegrini PR, Brandt R, et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 2004; 64(14): 4931–41PubMedCrossRefGoogle Scholar
  57. 57.
    Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007; 8(11): 975–84PubMedCrossRefGoogle Scholar
  58. 58.
    Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005; 65(10): 4389–400PubMedCrossRefGoogle Scholar
  59. 59.
    Drevs J, Siegert P, Medinger M, et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007; 25(21): 3045–54PubMedCrossRefGoogle Scholar
  60. 60.
    Ciardiello F, Caputo R, Damiano V, et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003; 9(4): 1546–56PubMedGoogle Scholar
  61. 61.
    Miller KD, Trigo JM, Wheeler C, et al. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 2005; 11(9): 3369–76PubMedCrossRefGoogle Scholar
  62. 62.
    Thomas AL, Trarbach T, Bartel C, et al. A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer. Ann Oncol 2007; 18(4): 782–8PubMedCrossRefGoogle Scholar
  63. 63.
    Suttle A, Hurwitz H, Dowlati A, et al. Pharmacokinetics (PK) and tolerability of GW786034, a VEGFR tyrosine kinase inhibitor, after daily oral administration to patients with solid tumors. J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition); 22(14 Suppl.): 3054Google Scholar
  64. 64.
    Hutson T, Davis I, Machiels J, et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): interim results of a phase II randomized discontinuation trial (RDT). J Clin Oncol 2007 ASCO Annual Meeting Prodeedings Part I; 25(18 Suppl.): 5031Google Scholar
  65. 65.
    Sonpavde G, Hutson TE, Sternberg CN. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert Opin Investig Drugs 2008; 17(2): 253–61PubMedCrossRefGoogle Scholar
  66. 66.
    Nakamura K, Taguchi E, Miura T, et al. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res 2006; 66(18): 9134–42PubMedCrossRefGoogle Scholar
  67. 67.
    Eskens F, Planting A, Van Doorn L, et al. An open-label phase I dose escalation study of KRN951, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 1 in a 4 week on, 2 week off schedule in patients with advanced solid tumors. J Clin Oncol 2006 ASCO Annual Meeting Proceedings; 24(18 Suppl.): 2034Google Scholar
  68. 68.
    Polverino A, Coxon A, Starnes C, et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 2006; 66(17): 8715–21PubMedCrossRefGoogle Scholar
  69. 69.
    Rosen L, Kurzrock R, Jackson E, et al. Safety and pharmacokinetics of AMG 706 in patients with advanced solid tumors. J Clin Oncol 2005 ASCO Annual Meeting Proceedings; 23(16 Suppl.): 3013Google Scholar
  70. 70.
    Rosen LS, Kurzrock R, Mulay M, et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007; 25(17): 2369–76PubMedCrossRefGoogle Scholar
  71. 71.
    Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001; 1(2): 118–29PubMedCrossRefGoogle Scholar
  72. 72.
    Tunon J, Ruiz-Moreno JM, Martin-Ventura JL, et al. Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration. Surv Ophthalmol 2009; 54(3): 339–48PubMedCrossRefGoogle Scholar
  73. 73.
    Hayek S, Scherrer M, Barthelmes D, et al. First clinical experience with an-ecortave acetate (Retaane). Klin Monatsbl Augenheilkd 2007; 224(4): 279–81PubMedCrossRefGoogle Scholar
  74. 74.
    Izumi-Nagai K, Nagai N, Ohgami K, et al. Inhibition of choroidal neovascularization with an anti-inflammatory carotenoid astaxanthin. Invest Ophthalmol Vis Sci 2008; 49(4): 1679–85PubMedCrossRefGoogle Scholar
  75. 75.
    Kaiser PK. Overview of radiation trials for age-related macular degeneration. Retina 2009; 29(6 Suppl.): S34–5PubMedCrossRefGoogle Scholar
  76. 76.
    Kymes S. The cost-effectiveness of treatment of age-related macular degeneration: a review. Minerva Med 2009; 100(1): 69–78Google Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  1. 1.The Pharmaceutical Research Institute (PRI)Albany College of Pharmacy and Health SciencesRensselaerUSA
  2. 2.Vascular Vision Pharmaceuticals Inc.WynantskillUSA

Personalised recommendations